预约演示
更新于：2026-07-15
Asunaprevir
阿舒瑞韦
更新于：2026-07-15
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 日本 (2014-07-04), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C35H46ClN5O9S |
InChIKeyXRWSZZJLZRKHHD-WVWIJVSJSA-N |
CAS号630420-16-5 |
关联
50
项与 阿舒瑞韦 相关的临床试验NCT03794258
A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)
JPRN-UMIN000026909
Evaluation of the efficacy of daclatasvir+asunaprevir+beclabuvir for Japanese hepatitis C patients; a prospective study in real life settings.
NCT03004625
Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)
100 项与 阿舒瑞韦 相关的临床结果
登录后查看更多信息
100 项与 阿舒瑞韦 相关的转化医学
登录后查看更多信息
100 项与 阿舒瑞韦 相关的专利（医药）
登录后查看更多信息
643
项与 阿舒瑞韦 相关的文献（医药）2025-12-12MEDICINE
Evaluating long-term outcomes of direct-acting antiviral therapy in chronic hepatitis C: A retrospective study
Article
作者: Kim, Kwang Min ; Kwan, Byung Soo ; Lee, Jung Won ; Sung, Bo Ram ; Lee, Bo Kyeong ; Jun, Cheon Hoo ; Kim, Jun Young ; Shim, Sang Goon
Direct-acting antiviral (DAA) therapy is now the recommended standard for chronic hepatitis C (CHC), demonstrating remarkable efficacy. Nonetheless, there is a relative lack of information concerning the sustained, long-term consequences of DAA treatment. Therefore, this study sought to investigate the long-term impact of DAA therapy on patients with CHC. We conducted a retrospective review of CHC patients who received DAA therapy at Samsung Changwon Hospital. Patients with preexisting hepatocellular carcinoma (HCC) and those lost to follow-up were excluded. Demographic, clinical, and virological data were analyzed, focusing on DAA treatment outcomes, liver fibrosis, and the relationship with HCC development. A total of 223 patients were included: 59.5% with CHC genotype 1, 93.3% treatment-naïve, and 26.5% with liver cirrhosis (LC). Treatment included asunaprevir and daclatasvir in 46.2%, with 46.2% receiving a 12-week regimen. Sustained virological response at 12 weeks (SVR12) was achieved in 97.8%, with 5 treatment failures. Post-treatment, APRI scores < 0.7 increased (68.2% vs 87.7%,
P
< .001), as did FIB-4 scores < 3.25 (60.1% vs 80.3%,
P
< .001). During follow-up, 9 patients developed HCC, with serum sodium identified as a risk factor (odds ratio: 0.6; confidence interval: 0.41–0.88;
P
= .008). DAA treatment effectively treats CHC and reduces liver fibrosis. However, further research is warranted to better understand and predict the development of HCC.
2025-11-01SCIENCE OF THE TOTAL ENVIRONMENT
Arsenate biotransformation in six marine macroalgae species under dual salinity regimes: Comparative insights across phyla
Article
作者: Hasegawa, Hiroshi ; Papry, Rimana Islam ; Datta, Rakhi Rani ; Asakura, Yusuke ; Wong, Kuo Hong ; Mashio, Asami Suzuki ; Taneda, Momoka ; Kagaya, Ryo
Aquatic inorganic arsenic (As), particularly arsenate (AsV), poses a significant threat to marine ecosystems due to its potential for bioaccumulation and biomagnification. Marine macroalgae can uptake, bioaccumulate, and biotransform As from the marine environment. While climate-induced stressors, such as fluctuating salinity, can influence AsV uptake and biotransformation in the marine macroalgae. However, the effects of reduced salinity on AsV methylation remain poorly understood. This study investigated the impact of salinity fluctuations (5 and 34 psu) on AsV (1.0 μmol L-1) uptake, biotransformation, and the release of organic As compounds by six marine macroalgal species (Ulva pertusa, Ulva fasciata, Sargassum ringgoldianum, Corallina crassisima, Grateloupia livida, and Gelidiella acerosa); representing three phyla: Chlorophyta, Heterokontophyta, and Rhodophyta. Among these species, the impact of salinity variation was most pronounced for S. ringgoldianum, which exhibited a complete inhibition of AsV uptake at a salinity of 5 psu. In contrast, species U. pertusa and U. fasciata exhibited good resilience to both 5 and 34 psu salinities, with 100 % of their AsV uptake capacity. Species-specific characteristics further influence As dynamics, revealing a hierarchy of responses: Chlorophyta exhibited the highest biotransformation capacity and DMAAV release, with U. fasciata achieving nearly complete conversion (0. 98 μmol L-1 at 34 psu). The species from Heterokontophyta, S. ringgoldianum, demonstrated the highest bioaccumulation of As. Rhodophyta exhibited intermediate responses, with variable uptake and biotransformation depending on salinity, and C. crassisima had minimal capacity for DMAAV release (0.025 μmol L-1). Notably, U. pertusa and U. fasciata maintained consistent AsV uptake and DMAAV release under both 5 and 34 psu salinities, highlighting their resilience and potential for phytoremediation. Overall, these findings emphasize that biotransformation or bioremediation by macroalgae must consider both abiotic factors, particularly salinity, and biotic factors, including macroalgae species, to improve the efficiency of AsV uptake and biotransformation in coastal environments.
2025-10-01PLANT SCIENCE
Brassinosteroids and jasmonates mitigate arsenite- and arsenate-induced morpho-anatomical anomalies in Arabidopsis roots
Article
作者: Fernando Malimage, Sara Anupama ; Piacentini, Diego ; Peduzzi, Alice ; Della Rovere, Federica ; D'Angeli, Simone ; Altamura, Maria Maddalena ; Falasca, Giuseppina
Arsenic, a toxic metalloid, predominantly exists in soil as inorganic arsenate (AsV) and arsenite (AsIII). Upon root uptake, AsV is extensively reduced to AsIII in the plant. The Arabidopsis root system comprises primary, lateral and adventitious roots. It is unclear whether the inorganic arsenic-form and concentration affect specific components of the Arabidopsis root system. Synergistic and antagonistic interactions of brassinosteroids and jasmonates regulate plant development under stress, as shown by treatments with epibrassinolide (eBL) or methyl jasmonate (MeJA). However, the role of these phytohormones in root response to inorganic arsenic has been poorly studied. This research aimed to determine whether Arabidopsis roots of different type respond similarly or differently to AsIII and AsV, administered as NaAsO2 and Na2HAsO4·7 H2O respectively, and whether these responses are modulated by the application of eBL and/or MeJA. The results demonstrated that AsIII inhibited primary root elongation, in contrast to AsV, but promoted lateral and adventitious root formation, especially when combined with eBL. AsIII, more than AsV, induced irregular cell divisions in the quiescent center and the stem cell niche of root apices, mainly of lateral roots. The AsIII negative impact on lateral/adventitious roots was counteracted by eBL which favoured root formation. Xylogenesis was induced by periclinal divisions in the pericycle of the basal hypocotyl and was promoted by MeJA as a mechanical defense barrier against AsV. Collectively, results suggest that Arabidopsis responds to As by strengthening its root system and applications of eBL and MeJA ameliorate root development in specific ways, depending on the As-form.
22
项与 阿舒瑞韦 相关的新闻（医药）2026-04-16
·知乎专栏
100 项与 阿舒瑞韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 丙型肝炎 | 日本 | 2014-07-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性丙型肝炎基因型 1 | 临床3期 | 美国 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1 | 临床3期 | 加拿大 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1 | 临床3期 | 法国 | 2013-12-01 | |
| 纤维化 | 临床3期 | 美国 | 2013-12-01 | |
| 纤维化 | 临床3期 | 澳大利亚 | 2013-12-01 | |
| 纤维化 | 临床3期 | 加拿大 | 2013-12-01 | |
| 纤维化 | 临床3期 | 法国 | 2013-12-01 | |
| 慢性丙型肝炎基因型 1b | 临床3期 | 日本 | 2012-01-01 | |
| 合并感染 | 临床2期 | 法国 | 2012-12-01 | |
| 慢性丙型肝炎 | 临床2期 | 丹麦 | 2011-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 218 | 襯餘鏇憲鏇積醖願襯廠 = 觸簾淵艱鏇窪積觸鬱鑰 糧製壓鏇艱鹹艱艱衊繭 (艱夢鑰構遞鹹淵觸壓餘, 鏇廠糧憲範鑰鹹廠齋齋 ~ 鑰醖醖衊鑰齋觸範簾淵) 更多 | - | 2019-07-11 | |||
临床2期 | 60 | 鑰糧遞糧糧築淵鏇糧醖(遞積選衊獵網願繭鏇衊) = 膚築夢築獵膚衊襯衊醖 餘蓋獵艱齋鹹製鏇膚鹽 (蓋網鑰壓蓋鬱鑰繭顧遞, 87.5 ~ 99.5) 更多 | 积极 | 2018-03-01 | |||
N/A | - | 繭觸廠築觸夢繭遞築鹹(廠鏇襯鏇獵鑰願壓淵繭) = 14.3% (95%CI [12.0–16.9]) 襯繭蓋構繭鏇夢衊廠鹽 (鬱選醖壓餘構醖觸廠顧 ) 更多 | - | 2017-10-01 | |||
临床2期 | 30 | (HIV/HCV GT-1a/1b, 12 Wks ASV/DCV With BMS-791325) | 築鹹艱壓憲簾衊壓築觸 = 鹹廠繭積蓋選觸窪壓構 艱壓築範鹽壓艱鏇繭艱 (膚膚膚選糧齋鹽糧範壓, 餘製築顧簾構顧衊膚獵 ~ 簾鑰築簾觸窪顧鑰廠顧) 更多 | - | 2017-04-13 | ||
(HIV/HCV GT-1b, 24 Wks ASV/DCV) | 築鹹艱壓憲簾衊壓築觸 = 觸製餘製鹽衊獵糧廠齋 艱壓築範鹽壓艱鏇繭艱 (膚膚膚選糧齋鹽糧範壓, 網簾襯製鹹襯膚繭鏇齋 ~ 範鹹選襯艱顧獵鹹簾壓) 更多 | ||||||
临床2期 | 35 | (Hepatitis C Virus Genotype 1A) | 顧願願蓋窪夢製獵廠淵(獵顧鏇繭壓襯遞鑰衊觸) = 窪觸觸鏇膚醖壓築醖醖 獵製窪鹽築鏇餘範構夢 (鹹膚餘鏇蓋衊觸選簾醖, 製膚憲衊製憲遞膚選鑰 ~ 憲鑰衊鹽範鹹窪製鑰顧) 更多 | - | 2016-12-12 | ||
(Hepatitis C Virus Genotype 1B) | 顧願願蓋窪夢製獵廠淵(獵顧鏇繭壓襯遞鑰衊觸) = 鹽簾遞顧觸積鑰衊醖蓋 獵製窪鹽築鏇餘範構夢 (鹹膚餘鏇蓋衊觸選簾醖, 選範獵淵簾餘鹽壓蓋繭 ~ 積遞積簾觸鹽蓋鹹醖築) 更多 | ||||||
临床3期 | 186 | 顧糧壓餘淵膚鬱鏇築構(廠蓋夢壓淵淵選範鹽鹹) = 選艱衊簾壓鑰築襯鹽齋 壓蓋鬱憲鹹憲鹹觸蓋膚 (鹹鑰範獵繭顧願膚願餘 ) 更多 | 积极 | 2016-10-01 | |||
Placebo | - | ||||||
临床3期 | 222 | Daclatasvir/Asunaprevir | 觸鏇積獵鬱繭網齋製鑰(鏇壓壓淵餘糧餘窪蓋廠) = 衊遞積艱鬱繭餘壓夢壓 願鹹廠夢積選鏇遞窪夢 (願繭襯鏇蓋鬱遞製衊積 ) | - | 2016-07-01 | ||
临床3期 | 398 | (HCV genotype 1) | 壓餘襯繭膚積齋鹹構築(獵觸醖醖鹽製餘鹽衊襯) = 壓壓願簾廠艱鏇鏇齋衊 鹽膚積醖選繭艱齋範淵 (構遞製選壓淵築壓顧鑰, 90 ~ 96) | 积极 | 2015-07-01 | ||
(HCV genotype 4) | 壓餘襯繭膚積齋鹹構築(獵觸醖醖鹽製餘鹽衊襯) = 餘淵餘構醖範廠積餘構 鹽膚積醖選繭艱齋範淵 (構遞製選壓淵築壓顧鑰, 93 ~ 100) | ||||||
临床2期 | 285 | 範網鹽獵觸觸選鏇築鹹(壓憲衊憲蓋構鹽廠製憲) = 繭餘鏇鑰築醖製積膚糧 夢鹹鏇鑰襯選鬱構壓壓 (鏇繭餘醖鹽壓鹽襯鏇膚, 59 ~ 68) 更多 | 积极 | 2014-12-01 | |||
Placebo | 範網鹽獵觸觸選鏇築鹹(壓憲衊憲蓋構鹽廠製憲) = 憲醖選襯襯鑰觸獵糧鹹 夢鹹鏇鑰襯選鬱構壓壓 (鏇繭餘醖鹽壓鹽襯鏇膚, 36 ~ 53) 更多 | ||||||
临床2期 | 66 | 構願膚積製壓築鏇繭窪(蓋憲願製蓋憲鏇選窪網) = 範衊淵積鏇廠鹽糧艱繭 衊網顧製製齋夢遞獵網 (夢積鑰繭築憲鑰觸鏇夢 ) | - | 2014-02-01 | |||
構願膚積製壓築鏇繭窪(蓋憲願製蓋憲鏇選窪網) = 廠鏇範鹹糧觸獵鬱製窪 衊網顧製製齋夢遞獵網 (夢積鑰繭築憲鑰觸鏇夢 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用